Trial site
Providence Milwaukie Hospital
Milwaukie, Oregon 97222, United StatesNot linked to an institution yet
- 15running trials
- 11closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 25 trials
- Phase 1/23 trials
- Status
- Active, not recruiting15 trials
- Completed11 trials
- Lead sponsor
- National Cancer Institute (NCI)18 trials
- Alliance for Clinical Trials in Oncology2 trials
- SWOG Cancer Research Network2 trials
- Eastern Cooperative Oncology Group1 trial
- ECOG-ACRIN Cancer Research Group1 trial
- and 2 more
Running trials
Active, not recruiting
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02048813· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
NCT01841736· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752· Phase 2· Eastern Cooperative Oncology Group· Source
Active, not recruiting
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT01522976· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT01169337· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
NCT01064648· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Dinaciclib in Treating Patients With Stage IV Melanoma
NCT00937937· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00658814· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00602641· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
NCT00569127· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
NCT00499330· Alliance for Clinical Trials in Oncology· Source
Report an error